Don't let this ETF's recent weak performance deter you from considering a long-term position for its income-producing potential.

Merck & Company, Inc. (NYSE:MRK) is one of the high-margin pharma stocks to buy now. Jefferies has raised its price target on ...

Merck & Co., Inc. (NYSE:MRK) is one of the Most Undervalued High Quality Stocks to Buy According to Hedge Funds. On July 10, Morgan Stanley analyst Terence Flynn lowered the firm’s price target on ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Merck & Co., Inc. outshines Gilead Sciences, Inc. with stronger dividend growth, valuation metrics & PEGY ratio. Click for ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Johnson & Johnson's stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average's DJIA early gainers. Shares of rival Pfizer Inc. (PFE) were up 0.3% in premarket trades and ...

Merck (NYSE:MRK) recently announced the initiation of its Phase 3 EXPrESSIVE clinical trials for MK-8527, a new HIV prevention drug, reflecting its commitment to addressing global health challenges.

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Analysts from Cantor Fitzgerald downgraded Merck’s FY2025 EPS forecast from $8.88 to $8.66 while maintaining a cautious ...